Literature DB >> 15738532

Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal.

Emili Montserrat.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15738532     DOI： 10.1200/JCO.2005.11.932

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Vassiliki Pappa; Hellinida Thomadaki; Frida Kontsioti; John Dervenoulas; Efstathios Papageorgiou; Theofanis Economopoulos; Andreas Scorilas
Journal:  Oncologist       Date:  2011-07-07

2.  The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.

Authors:  Rodrigo Santacruz; Neus Villamor; Marta Aymerich; Alejandra Martínez-Trillos; Cristina López; Alba Navarro; María Rozman; Sílvia Beà; Cristina Royo; Maite Cazorla; Dolors Colomer; Eva Giné; Magda Pinyol; Xose S Puente; Carlos López-Otín; Elías Campo; Armando López-Guillermo; Julio Delgado
Journal:  Haematologica       Date:  2014-04-03       Impact factor: 9.941

Review 3.  Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.

Authors:  Tom Butler; J G Gribben
Journal:  Blood Rev       Date:  2010-04-15       Impact factor: 8.250

4.  Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.

Authors:  Anne Mette Buhl; Danelle F James; Donna Neuberg; Sonia Jain; Laura Z Rassenti; Thomas J Kipps
Journal:  Eur J Haematol       Date:  2011-03-23       Impact factor: 2.997

5.  Alemtuzumab in the up-front setting.

Authors:  Matthew Kaufman; Kanti R Rai
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

6.  A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Authors:  A C Rawstron; C Fazi; A Agathangelidis; N Villamor; R Letestu; J Nomdedeu; C Palacio; O Stehlikova; K-A Kreuzer; S Liptrot; D O'Brien; R M de Tute; I Marinov; M Hauwel; M Spacek; J Dobber; A P Kater; P Gambell; A Soosapilla; G Lozanski; G Brachtl; K Lin; J Boysen; C Hanson; J L Jorgensen; M Stetler-Stevenson; C Yuan; H E Broome; L Rassenti; F Craig; J Delgado; C Moreno; F Bosch; A Egle; M Doubek; S Pospisilova; S Mulligan; D Westerman; C M Sanders; R Emerson; H S Robins; I Kirsch; T Shanafelt; A Pettitt; T J Kipps; W G Wierda; F Cymbalista; M Hallek; P Hillmen; E Montserrat; P Ghia
Journal:  Leukemia       Date:  2015-12-07       Impact factor: 11.528

7.  Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Authors:  Philip A Thompson; Christine B Peterson; Paolo Strati; Jeff Jorgensen; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan A Burger; Zeev Estrov; Nitin Jain; Tapan M Kadia; Gautam Borthakur; Courtney D DiNardo; Naval Daver; Elias Jabbour; William G Wierda
Journal:  Leukemia       Date:  2018-04-17       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.